These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2473757)

  • 41. Antigenicity of a viral peptide displayed on beta-galactosidase fusion proteins is influenced by the presence of the homologous partner protein.
    Corchero JL; Villaverde A
    FEMS Microbiol Lett; 1996 Nov; 145(1):77-82. PubMed ID: 8931330
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modified-live infectious bovine rhinotracheitis virus (IBRV) vaccine expressing foot-and-mouth disease virus (FMDV) capsid protein epitopes on surface of hybrid virus particles.
    Kit S; Kit M; DiMarchi R; Little S; Gale C
    Adv Exp Med Biol; 1991; 303():211-20. PubMed ID: 1725233
    [No Abstract]   [Full Text] [Related]  

  • 43. Nucleotide sequence and corresponding amino acid sequence of the gene for the major antigen of foot and mouth disease virus.
    Kurz C; Forss S; Küpper H; Strohmaier K; Schaller H
    Nucleic Acids Res; 1981 Apr; 9(8):1919-31. PubMed ID: 6264400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibodies against a preselected peptide recognize and neutralize foot and mouth disease virus.
    Pfaff E; Mussgay M; Böhm HO; Schulz GE; Schaller H
    EMBO J; 1982; 1(7):869-74. PubMed ID: 6203738
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential restrictions on antigenic variation among antigenic sites of foot-and-mouth disease virus in the absence of antibody selection.
    Holguín A; Hernández J; Martínez MA; Mateu MG; Domingo E
    J Gen Virol; 1997 Mar; 78 ( Pt 3)():601-9. PubMed ID: 9049411
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful mimicry of a complex viral antigen by multiple peptide insertions in a carrier protein.
    Feliu JX; Carbonell X; Villaverde A
    FEBS Lett; 2000 May; 474(1):87-92. PubMed ID: 10828457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular cloning and expression of the VP1 gene of foot-and-mouth disease virus C1 in E. coli: effect on bacterial cell viability.
    Vidal M; Cairó J; Mateu MG; Villaverde A
    Appl Microbiol Biotechnol; 1991 Sep; 35(6):788-92. PubMed ID: 1369359
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The molecular basis of the antigenic variation of foot-and-mouth disease virus.
    Beck E; Feil G; Strohmaier K
    EMBO J; 1983; 2(4):555-9. PubMed ID: 6194987
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The position of the heterologous domain can influence the solubility and proteolysis of beta-galactosidase fusion proteins in E. coli.
    Corchero JL; Viaplana E; Benito A; Villaverde A
    J Biotechnol; 1996 Jul; 48(3):191-200. PubMed ID: 8861998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topology of PhoE porin: the 'eyelet' region.
    Struyvé M; Visser J; Adriaanse H; Benz R; Tommassen J
    Mol Microbiol; 1993 Jan; 7(1):131-40. PubMed ID: 7679770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Uses of beta-galactosidase tag in on-line monitoring production of fusion proteins and gene expression in Escherichia coli.
    Benito A; Valero F; Lafuente J; Vidal M; Cairo J; Solà C; Villaverde A
    Enzyme Microb Technol; 1993 Jan; 15(1):66-71. PubMed ID: 7764038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlations between the conformations elucidated by CD spectroscopy and the antigenic properties of four peptides of the foot-and-mouth disease virus.
    Siligardi G; Drake AF; Mascagni P; Rowlands D; Brown F; Gibbons WA
    Eur J Biochem; 1991 Aug; 199(3):545-51. PubMed ID: 1651235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Engineering of Escherichia coli beta-galactosidase for solvent display of a functional scFv antibody fragment.
    Alcalá P; Ferrer-Miralles N; Villaverde A
    FEBS Lett; 2003 Jan; 533(1-3):115-8. PubMed ID: 12505169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beta-galactosidase enzymatic activity as a molecular probe to detect specific antibodies.
    Benito A; Feliu JX; Villaverde A
    J Biol Chem; 1996 Aug; 271(35):21251-6. PubMed ID: 8702899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Difference in the production of human interferon-alpha and -beta in mouse cells.
    Toth MI; Cendsuren O; Endresz V; Karcagi I; Duda E
    J Gen Virol; 1988 Oct; 69 ( Pt 10)():2527-33. PubMed ID: 3171550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Using genetically engineered bacteria for vaccine production.
    Kleid DG
    Ann N Y Acad Sci; 1983; 413():23-30. PubMed ID: 6322643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A cell adhesion peptide from foot-and-mouth disease virus can direct cell targeted delivery of a functional enzyme.
    Villaverde A; Feliu JX; Arís A; Harbottle RP; Benito A; Coutelle C
    Biotechnol Bioeng; 1998 Aug; 59(3):294-301. PubMed ID: 10099340
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of outer membrane protein PhoE as a carrier for the transport of a foreign antigenic determinant to the cell surface of Escherichia coli K-12.
    Agterberg M; Adriaanse H; Tommassen J
    Gene; 1987; 59(1):145-50. PubMed ID: 2449378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A tandem repeat gene in a picornavirus.
    Forss S; Schaller H
    Nucleic Acids Res; 1982 Oct; 10(20):6441-50. PubMed ID: 6294604
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The N-terminal amino acid sequence is essential for foot-and-mouth disease virus replicase activity.
    Pacheco AB; Brindeiro RM; Soares MA; de-Almeida DF; Tanuri A
    Braz J Med Biol Res; 1992; 25(7):659-66. PubMed ID: 1342596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.